WHO ICTRP trial
A randomized, double-blind, placebo-controlled, study evaluating the efficacy…
NL-OMON55089 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON55089 |
|---|---|
| Public title | A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease (study 214094) |
| Scientific title | A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease (study 214094) - study 214094, OSCAR |
| Primary sponsor | GlaxoSmithKline |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Argentina;Belgium;Brazil;Canada;Chile;France;India;Japan;Mexico;Netherlands;Peru;Poland;Russian Federation ;South Africa;Spain;Sweden;United Kingdom;United States of America |
| Conditions | COVID-19 related lung disease; coronavirus related lung disease;10047438;10024970;COVID-19 related lung disease; coronavirus related lung disease |
| Interventions | Half of the group wil receive a single IV injection with otilimab 90 mg, the other half will receive a single IV injection with placebo. ;COVID-19;Otilimab;placebo-controlled |
| Registration date | Feb 2, 2021 |
| Target size | 68 |
| Secondary IDs | 2020-001759-42;NL74071.056.20 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: